SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.019
AS - Asia 5.802
EU - Europa 3.493
SA - Sud America 891
AF - Africa 83
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 22.308
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.787
SG - Singapore 2.279
CN - Cina 1.802
DE - Germania 839
BR - Brasile 748
HK - Hong Kong 582
UA - Ucraina 544
IT - Italia 540
TR - Turchia 490
GB - Regno Unito 388
VN - Vietnam 270
FI - Finlandia 268
SE - Svezia 239
RU - Federazione Russa 216
MX - Messico 120
PL - Polonia 110
FR - Francia 92
CA - Canada 91
IN - India 85
ID - Indonesia 76
AR - Argentina 58
ZA - Sudafrica 48
JP - Giappone 45
BD - Bangladesh 42
BE - Belgio 42
CZ - Repubblica Ceca 41
NL - Olanda 38
EC - Ecuador 33
IQ - Iraq 29
AT - Austria 28
ES - Italia 28
LT - Lituania 26
UZ - Uzbekistan 14
CL - Cile 11
AU - Australia 10
CO - Colombia 10
IL - Israele 9
KE - Kenya 9
PK - Pakistan 9
KR - Corea 8
NP - Nepal 8
PY - Paraguay 8
RO - Romania 7
UY - Uruguay 7
DK - Danimarca 6
DO - Repubblica Dominicana 6
EG - Egitto 6
IE - Irlanda 6
MA - Marocco 6
SA - Arabia Saudita 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
CH - Svizzera 5
EU - Europa 5
IR - Iran 5
PE - Perù 5
BH - Bahrain 4
DZ - Algeria 4
KZ - Kazakistan 4
QA - Qatar 4
BO - Bolivia 3
JO - Giordania 3
LV - Lettonia 3
MY - Malesia 3
PT - Portogallo 3
TN - Tunisia 3
AL - Albania 2
BB - Barbados 2
BY - Bielorussia 2
EE - Estonia 2
ET - Etiopia 2
GD - Grenada 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SR - Suriname 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
GR - Grecia 1
GT - Guatemala 1
JM - Giamaica 1
KW - Kuwait 1
Totale 22.294
Salva come PNG Salva come JPEG
Città #
Singapore 1.293
Woodbridge 1.238
Ashburn 1.210
Fairfield 1.181
Houston 830
Beijing 748
Chandler 648
Jacksonville 627
Hong Kong 581
Santa Clara 557
Ann Arbor 487
Seattle 458
Wilmington 429
Cambridge 379
Dallas 266
Los Angeles 231
New York 231
Izmir 227
Nanjing 199
Munich 192
Princeton 170
Ferrara 154
Boardman 119
San Diego 112
Warsaw 106
Shanghai 99
Ho Chi Minh City 95
Addison 90
Turku 86
São Paulo 84
Mexico City 82
Milan 76
Shenyang 67
Nanchang 64
Helsinki 62
Jakarta 61
Hanoi 57
London 55
Chicago 50
Bremen 45
Hebei 45
The Dalles 44
Brussels 42
Stockholm 40
Buffalo 39
Denver 39
Brooklyn 38
Rio de Janeiro 38
Tianjin 37
Hefei 36
Montreal 34
Falls Church 33
Tokyo 33
Columbus 32
Moscow 32
Redwood City 32
Changsha 31
Jinan 31
Johannesburg 31
Chennai 30
Phoenix 30
Falkenstein 29
San Francisco 29
Poplar 28
Boston 27
Jiaxing 27
Atlanta 25
Brno 25
Manchester 23
Mountain View 23
Toronto 23
Zhengzhou 23
Dong Ket 22
Frankfurt am Main 22
Orem 22
Dearborn 21
Norwalk 19
Des Moines 17
Salt Lake City 17
San Jose 17
Belo Horizonte 16
Fidenza 16
Guangzhou 16
Nuremberg 16
Kunming 15
Rome 15
San Mateo 15
Ankara 14
Ningbo 14
Orange 13
Querétaro 13
Auburn Hills 12
Brasília 12
Guayaquil 12
Leawood 12
Olomouc 12
Quito 12
Baghdad 11
Curitiba 11
Tappahannock 11
Totale 15.200
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 260
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 237
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 232
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 225
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 225
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 219
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 217
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 216
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 216
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 215
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 213
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 212
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 212
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 212
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 205
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 204
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 202
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 194
Secondary chromosome changes in mantle cell lymphoma: Cytogenetic and fluorescence in situ hybridization studies 192
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 191
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 191
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 190
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 188
Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features 187
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 187
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 186
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 186
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 185
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 185
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 184
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 183
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 182
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 179
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 178
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 176
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 173
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 173
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 173
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 171
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 170
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 170
Hepatosplenic T-cell lymphoma (HSTCL). 167
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 165
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 164
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 163
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 162
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 159
Multilineage involvement in the 5q- syndrome: A fluorescent in situ hybridization study on bone marrow smears 158
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 158
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 158
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 156
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 156
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 155
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 155
Intestinal T-cell lymphoma 154
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 154
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 154
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 154
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 153
In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome 153
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 149
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 147
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 146
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 146
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 145
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 144
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 143
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 142
Neoplastic circulating endothelial cells in hematologic malignancies 142
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 140
Differences among young adults, adults and elderly chronic myeloid leukemia patients 140
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 139
Essential Thrombocythemia (ET) 139
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia 138
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 138
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 137
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 135
LATE APPEARANCE of 14q32/IGH TRANSLOCATION In CHRONIC LYMPHOCYTIC LEUKEMIA. 132
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 131
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 130
Clinicobiological features in chronic lymphocytic leukemia with 14q32/IgH translocations. 130
Molecular cytogenetic lesions in chronic lymphocytic leukemia 129
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 129
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 129
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 126
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 124
null 124
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 124
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 124
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 123
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia 121
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 120
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 120
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 119
Imatinib In Very Elderly CML Patients: What Can We Achieve? 118
IN CHRONIC LYMPHOCYTIC LEUKEMIA THE AMOUNT OF PROLIFERATION CENTERS IN TISSUE-BIOPSIES CORRELATES WITH UNFAVORABLE CYTOGENETIC ABNORMALITIES 117
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 117
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB 115
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results 115
Il percorso diagnostico. 114
Totale 16.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.056
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.789
Totale 117.845
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.461 0 0 0 0 0 200 71 241 41 322 396 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024780 79 91 37 18 38 143 42 54 24 16 26 212
2024/20253.717 94 102 273 101 488 363 68 149 648 406 510 515
2025/20265.780 993 566 907 1.465 1.626 223 0 0 0 0 0 0
Totale 22.606